News
ImmuneRegen News
Terrorism Preparedness Advocate Available To Comment on Inadequate State of Homeland Readiness
Michael Wilhelm Warns That London Disaster Points to U.S. Vulnerability to
Bio-terror Attack
In the wake of another major terrorist attack, Michael Wilhelm, co-founder and CEO of ImmuneRegen BioSciences is currently available for interview on the terrorist threat of biological, chemical, and radiological warfare, and can explain how our country’s own bureaucratic processes may end up costing countless lives.
As the CEO of a start-up biotech company, Wilhelm has become an advocate for bioterrorism preparedness. He has spent hundreds of hours working with government officials and other homeland security professionals to raise the level of bioterrorism preparedness in the U.S. and to cut the red tape that is holding back the development of lifesaving treatments and antidotes for threats such as anthrax and radiation.
“The London bombings could have taken a considerably larger number of lives had the terrorists utilized nuclear bombs or known biological agents such as anthrax or avian flu,” warns Wilhelm. “It is saddening to think of the lives affected by this horrific tragedy. We offer our assistance to globally increase preparedness should a similar incident involving bioterrorism happen in London or elsewhere. The terrorists' complete disregard for human life is a powerful indicator that a major bioterror attack is an inevitable reality. However, our country is just not ready for that.”
FDA Mandate
Part of Wilhelm’s efforts has included the creation of the Bioterrorism Preparedness Advisory Board. This board is comprised of knowledgeable military and private citizens that possess first hand experience in combat casualty and mass trauma scenarios, including preparation for a bioterrorist attack. Created in response to the request of the USFDA Division of Counterterrorism, the Advisory Board has been charged with developing an emergency deployment plan for Immuneregen’s proprietary compound, Radilex™. He is also currently working with the office of Senator Joseph Lieberman on the development of BioShield II, a new bio-defense bill geared toward increasing the level of readiness for biological warfare.
Wilhelm is qualified to provide in-depth commentary on the following issues:
- How the development of preventative measures are being delayed by our own government as a result of agency- and administration-related red tape
- How smaller bio-tech companies, with efficacious treatments, are dying in the “valley of death” created by this issue
How our emergency stations are not adequately stocked with the appropriate treatments and medications to prevent/treat the ill effects of bioterrorist warfare agents
- The solutions offered by the Bioshield II legislation to push though the barrier of official procedure and begin manufacturing and stockpiling treatments
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO), is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the company's website at www.immuneregen.com.
About ImmuneRegen BioSciences, Inc.
a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Contact:
Amendola Communications for ImmuneRegen
Jan Shulman, 480-664-8412 ext. 12
jshulman@ACmarketingPR.com
or
Jodi Amendola, 480-664-8412 ext 11
jamendola@ACmarketingPR.com
###
Copyright © 2003-2008, ImmuneRegen Biosciences, Inc.
All rights reserved.